Washington University School of Medicine
This study hypothesizes that PMD-026, an oral inhibitor of ribosomal protein S6 kinase A1 (RSK1), is safe and well tolerated in participants with myelofibrosis (MF) and myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPNs) and will improve spleen response, symptom response, and bone marrow histopathological response.
Inclusion Criteria: * Histologically confirmed diagnosis of one of the following myeloid neoplasms determined by pathology review: * Primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis in chronic phase according to the 2016 WHO criteria. * Patients with MF must have had at least 1 prior JAK inhibitor treatment for a minimum of 12 weeks and their disease must have been determined to be resistant or refractory, and/or their response must have been lost or intolerant to treatment. * MF must be Intermediate-2 or High-risk MF, as…
PMD-026 is an oral drug which will be taken every 12 hours on an outpatient basis at the assigned dose every day of each 28-day cycle. Provided by Phoenix Molecular Designs.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.